معرفی
Dr. Thijs Giezen serves as a Researcher in the Department of Pharmacoepidemiology and Clinical Pharmacology within the Faculty of Science at Utrecht University. His work primarily focuses on the safety, efficacy, and regulatory aspects of biological medicines, with particular expertise in biosimilars and TNF inhibitors.
Dr. Giezen's research interests center on pharmacoepidemiology and clinical pharmacology, with specific emphasis on biosimilar medicines, pharmacovigilance systems, drug safety monitoring, and regulatory science. His work investigates critical issues such as biosimilar retransitioning patterns, quality attribute reporting, post-approval manufacturing changes, and the safety profiles of biological therapeutics. He has conducted extensive research comparing information from regulatory authorities versus scientific publications, particularly regarding TNF inhibitors and other biologics.
Analysis of Dr. Giezen's publication record reveals a strong focus on biosimilar medicines and their clinical implementation. His work spans regulatory science, clinical outcomes research, and methodological approaches to pharmacovigilance. Key themes include biosimilar switching and retransitioning patterns, quality attribute assessment, TNF inhibitor safety, and comparative analyses of regulatory versus scientific reporting standards. His research often employs systematic review methodologies, observational studies, and database analyses to address critical questions in biologic medicine safety and utilization.
Dr. Giezen completed his doctoral thesis at Utrecht University in 2011 titled "Risk management of biologicals: a regulatory and clinical perspective," which established the foundation for his subsequent research trajectory in biologic medicine safety. His work has been cited extensively, with numerous publications appearing in high-impact journals including Drug Safety, British Journal of Clinical Pharmacology, and BioDrugs. The research output demonstrates consistent productivity with 39 publications spanning from 2007 to 2024, indicating sustained scholarly contribution to the field.
